Neuren Pharmaceuticals Limited

ASX (AUD): Neuren Pharmaceuticals Limited (NEU)

Last Price

12.43

Today's Change

-1.26 (9.20%)

Day's Change

12.42 - 13.68

Trading Volume

1,147,833

Profile
NEU

Exchange:  Australian Securities Exchange Australian Securities Exchange

Currency:  AUD AUD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.

Full Time Employees:  0 0

IPO Date:  2005-02-01 2005-02-01

CIK: 

ISIN:  NZNEUE0001S8 NZNEUE0001S8

CUSIP:  Q6634F109 Q6634F109

Beta:  2.17 2.17

Last Dividend:  0.00 0.00

Dcf Diff:  21.69 21.69

Dcf:  -1.98 -1.98

Description

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Address

697 Burke Road,
Camberwell, VIC 3124, AU

61 3 9092 0480

http://www.neurenpharma.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment